Silverarc Capital Management’s Benitec Biopharma BNTC Stock Holding History

Silverarc Capital Management’s Portfolio BNTC Stock Details BNTC Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$9.1M	Sell	679,826 -37,899	-5%	-$450K	0.95%	35
2026 Q1	$7.64M	Sell	717,725 -13,992	-2%	-$162K	0.78%	33
2025 Q4	$9.86M	Buy	731,717 +455,450	+165%	+$6.3M	1.37%	24
2025 Q3	$3.88M	Buy	276,267 +23,033	+9%	+$294K	0.52%	50
2025 Q2	$2.96M	Buy	253,234 +3,234	+1%	+$45.2K	0.55%	41
2025 Q1	$3.25M	Buy	+250,000	New	+$3.02M	0.67%	43
2022 Q2	–	Sell	-28,993	Closed	-$57K	–	74
2022 Q1	$57K	Sell	28,993 -5,566	-16%	-$231K	0.02%	66
2021 Q4	$1.54M	Buy	34,559 +5,264	+18%	+$294K	0.62%	47
2021 Q3	$1.78M	Buy	29,295 +1,809	+7%	+$119K	1.01%	35
2021 Q2	$1.99M	Buy	+27,486	New	+$2.15M	0.89%	40

Other funds holding BNTC

SCM

Suvretta Capital Management New York $5.47B AUM 131.34% 1-Year Est. Return

Jupiter Topco New York $245B AUM

Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return

NCM

Nantahala Capital Management New Canaan, Connecticut $3.01B AUM 119.46% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

SAM

Simplify Asset Management Las Vegas, Nevada $7.19B AUM 6.88% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

IAM

Infinitum Asset Management Fort Lauderdale, Florida $983M AUM 26.53% 1-Year Est. Return

Silverarc Capital Management's BNTC Position: Q2 2026 in Review

Silverarc Capital Management reduced its Benitec Biopharma (BNTC) stake by 5.3% in Q2 2026, selling an estimated $450K and leaving 679,826 shares worth $9.1M. The position accounts for 0.95% of the portfolio, ranked #35.

Silverarc Capital Management first reported a position in BNTC in Q2 2021 and has held it in 10 quarters since. The position peaked at $9.86M in Q4 2025. 87 funds tracked by Wall St. Rank hold BNTC as of Q2 2026.

Silverarc Capital Management held 679,826 shares of Benitec Biopharma worth $9.1M as of Q2 2026.
Silverarc Capital Management sold 37,899 Benitec Biopharma shares in Q2 2026, an estimated $450K.
Benitec Biopharma made up 0.95% of Silverarc Capital Management's portfolio in Q2 2026, its #35 holding.
Silverarc Capital Management first reported a position in Benitec Biopharma in Q2 2021 and has held it in 10 quarters since.
Silverarc Capital Management's Benitec Biopharma position peaked at $9.86M in Q4 2025.
87 funds tracked by Wall St. Rank held Benitec Biopharma as of Q2 2026.

Based on Silverarc Capital Management's 13F filing for Q2 2026, filed 13 Aug 2026.